Sentynl and PRG partner for Progerinin licence
Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational molecule…
16 Mar 2026
Most London patients go private to access weight loss drugs
The majority of patients in London taking weight loss medications are doing so privately, with slow rollouts meaning only a fraction of eligible patients are accessing the drugs on the…
16 Mar 2026
GSK’s RSV jab secures FDA label expansion to larger adult population
GSK has secured a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, from the US Food and Drug Administration (FDA) – broadening the jab’s commercial reach on American…
16 Mar 2026
Biophytis and LynxKite expand alliance to boost AI-driven drug discovery
Biophytis has expanded its existing partnership with LynxKite Technologies to accelerate AI-driven longevity drug discovery, beginning with the MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy (MASSIVE) project.…
16 Mar 2026
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients
Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients aged 12 years and above with moderate to severe hidradenitis suppurativa (HS). This…
13 Mar 2026
Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial approaches remain critical barriers to innovation, says a field expert.…
13 Mar 2026
WHO directs antibiotic development to priority pathogens
The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a move to direct research towards developing urgently needed antibiotics. The three Target…